Financial Performance - The company reported net revenue of $110.837 million for the year ended December 31, 2024, a decrease of 5.2% from $117.059 million in 2023[261] - Adjusted EBITDA for 2024 was $24.057 million, significantly up from $15.429 million in 2023, representing a year-over-year increase of 55.5%[261] - The company achieved a GAAP net income of $7.851 million in 2024, compared to a net loss of $48.674 million in 2023[261] - Adjusted operating income for 2024 was $11.455 million, up from $5.967 million in 2023, resulting in an adjusted operating margin of 10.3% compared to 5.1% in the previous year[264] - Non-GAAP adjusted net income for 2024 was $10.520 million, compared to $4.801 million in 2023, indicating a substantial improvement in profitability[264] - The company reported a non-GAAP adjusted earnings per share of $0.65 for 2024, an increase from $0.30 in 2023[266] - The company’s GAAP operating margin improved to 8.2% in 2024 from a negative 40.2% in 2023[264] - Operating income for 2024 was $9,121,000, compared to an operating loss of $47,115,000 in 2023[267] - Net income for 2024 was $7,851,000, a significant improvement from a net loss of $48,674,000 in 2023[267] - Net income attributable to common shareholders was a loss of $4,459,000 in 2024, an improvement from a loss of $64,348,000 in 2023[267] Expenses and Cost Management - The company’s offshore operations accounted for approximately 15% of total expenses in 2024, up from 9% in 2023, with personnel-related costs making up about 75% of these expenses[256] - Total operating expenses decreased to $101,716,000 in 2024 from $164,174,000 in 2023, reflecting a reduction of 38%[267] - Direct operating costs represented about 13% of total costs in 2024, compared to 11% in 2023, indicating a slight increase in operational efficiency[282] - General and administrative expenses accounted for approximately 22% of total expenses in 2024, up from 17% in 2023, suggesting increased administrative costs[284] - Selling and marketing expenses decreased by $3.4 million or 35% to $6.2 million in 2024 from $9.7 million in 2023[314] - General and administrative expenses decreased by $5.3 million or 25% to $16.1 million in 2024 from $21.5 million in 2023[315] - Research and development expenses decreased by $955,000 or 20% to $3.8 million in 2024 from $4.7 million in 2023[316] - Total operating expenses for 2024 were $101.7 million, a decrease of $62.5 million or 38% from $164.2 million in 2023[313] Cash Flow and Financial Position - Cash balance increased to $5,145,000 in 2024 from $3,331,000 in 2023[268] - Positive cash flow from operations increased to $20.6 million in 2024 from $15.5 million in 2023, representing a 34% increase[331] - Cash used in investing activities decreased to $7.4 million in 2024 from $11.6 million in 2023, a reduction of $4.2 million[336] - Cash used in financing activities was $11.3 million in 2024, down from $13.3 million in 2023, including the full repayment of a $10 million credit line[337] - The company recorded a net increase in cash of $1.8 million in 2024, compared to a decrease of $8.9 million in 2023, marking a turnaround of $10.8 million[331] Client and Revenue Metrics - The company served approximately 40,000 providers across about 2,600 practices as of December 31, 2024, maintaining a stable client base[275] - Customer renewal rates improved to 95% in 2024 from 91% in 2023, reflecting strong client retention[276] - Revenue from technology-enabled business solutions accounted for approximately 67% of total revenues in 2024, up from 65% in 2023[277] - Revenue from technology-enabled business solutions was $73.7 million in 2024, down from $76.6 million in 2023[310] - Professional services revenue decreased by $4.8 million in 2024 compared to 2023, primarily due to the winding down of services for two large accounts[311] Goodwill and Impairment - Goodwill impairment charges in 2023 amounted to $42,000,000, reflecting a significant write-down related to the Healthcare IT reporting unit[287] - Goodwill impairment of approximately $2 million was recorded in October 2023, with an additional impairment of approximately $40 million recorded in December 2023[305] - Goodwill impairment charge of $42 million was recorded in 2023, resulting in the reversal of the entire deferred tax liability at December 31, 2023[325] Shareholder Information - The total fully diluted shares increased to 16,498,736 in 2024 from 16,614,000 in 2023[266] - The weighted average common shares outstanding increased to 16,146,975 in 2024 from 15,669,472 in 2023[267] - Shareholders' equity increased to $49,774,000 in 2024 from $41,717,000 in 2023[268] Tax and Interest - The income tax provision for 2024 was $160,000, contrasting with a tax benefit of $364,000 in 2023[323] - Interest income decreased by $66,000 or 43% to $88,000 for the year ended December 31, 2024, compared to $154,000 in 2023[320] - Interest expense decreased by $294,000 or 25% to $900,000 for the year ended December 31, 2024, from $1.2 million in 2023[321] - Other expense - net improved to $298,000 in 2024 from $883,000 in 2023, primarily due to a foreign exchange gain of $130,000 compared to a loss of $790,000 in 2023[322] Future Outlook - The company plans to continue leveraging its offshore operations to maintain competitive cost advantages in the healthcare IT sector[256] - The company expects to achieve further economies of scale as it grows, potentially reducing direct operating costs as a percentage of revenue[282] - The company has a total federal NOL carry forward of approximately $265 million, with $187 million expiring between 2031 and 2038[328]

CareCloud, Inc. (NASDAQ:CCLD) Q4 2024 Earnings Conference Call March 13, 2025 8:30 AM ET Company Participants Kristen Rothe - Corporate Counsel Stephen Snyder - Co-Chief Executive Officer Hadi Chaudhry - Co-Chief Executive Officer & Director Norman Roth - Interim Chief Financial Officer & Corporate Controller Mahmud Haq - Founder & Executive Chairman Conference Call Participants Michael Kim - Zacks Small-Cap Research Jeffrey Cohen - Ladenburg Thalmann Allen Klee - Maxim Group Operator Greetings, and welcome ...

CareCloud (CCLD) Q4 2024 Earnings Call March 13, 2025 08:30 AM ET Company Participants Kristen Rothe - Corporate Counsel and Privacy OfficerStephen Snyder - Co- CEOHadi Chaudhry - CEO & PresidentNorman Roth - Interim CFO, Principal Accounting Officer & ControllerMahmud Haq - Founder & Executive ChairmanJeffrey Scott Cohen - Director of Research Conference Call Participants Michael Kim - Senior AnalystAllen Klee - MD & Senior Research Analyst Operator Greetings, and welcome to the CareCloud Fourth Quarter tw ...

Q4 2024 RESULTS Nasdaq Global Market: CCLD, CCLDP, CCLDO March 13, 2025 A leading provider of technology-enabled services and solutions that redefine the healthcare revenue cycle © CareCloud, Inc. 2025 Safe Harbor Statements This presentation contains forward-looking statements within the meaning of the federal securities laws. These statements relate to anticipated future events, future results of operations or future financial performance. In some cases, you can identify forward-looking statements by term ...

Financial Performance - GAAP net income for full year 2024 was $7.9 million, a significant turnaround from a net loss of $48.7 million in 2023[5] - Adjusted EBITDA for full year 2024 increased by 56% to $24.1 million, up from $15.4 million in 2023[5] - Free cash flow for full year 2024 reached $13.2 million, representing a 244% increase from $3.8 million in 2023[5] - Fourth quarter 2024 GAAP net income was $3.3 million, compared to a net loss of $43.7 million in Q4 2023[8] - Adjusted EBITDA for Q4 2024 was $7.1 million, or 25% of revenue, up from $4.1 million in the same period last year[9] - Operating income for the year ended December 31, 2024, was $9,121, compared to a loss of $47,115 in 2023, indicating a significant turnaround[31] - Net income for the year ended December 31, 2024, was $7,851, compared to a net loss of $48,674 in 2023, reflecting improved financial performance[31] - GAAP net income for Q4 2024 was $3,296,000, a significant improvement compared to a loss of $43,692,000 in Q4 2023; for the year, net income was $7,851,000 compared to a loss of $48,674,000 in 2023[41] - Non-GAAP adjusted operating income for Q4 2024 was $3,940,000, up from $1,191,000 in Q4 2023, with a non-GAAP adjusted operating margin of 14.0% compared to 4.2% in the same quarter last year[39] - Non-GAAP adjusted net income for Q4 2024 was $3,871,000, compared to $835,000 in Q4 2023, resulting in a non-GAAP adjusted net income per share of $0.24 versus $0.05[41] Revenue and Cash Flow - Revenue for full year 2024 was $110.8 million, a decrease from $117.1 million in 2023[6] - Total net revenue for the year ended December 31, 2024, was $110,837, a decrease of 5.2% from $117,059 in 2023[31] - Net revenue for Q4 2024 was $28,239,000, a slight decrease from $28,416,000 in Q4 2023, while total revenue for the year decreased from $117,059,000 in 2023 to $110,837,000 in 2024[39] - Free cash flow for Q4 2024 was $2,967,000, an increase from $1,449,000 in Q4 2023, while annual free cash flow rose to $13,236,000 from $3,848,000[45] - Cash at the end of the year increased to $5,145 from $3,331, marking a 54.4% increase[33] - Net cash provided by operating activities for Q4 2024 was $5,229,000, up from $3,740,000 in Q4 2023[45] Cost Management and Liabilities - Total operating expenses for the year decreased to $101,716 in 2024 from $164,174 in 2023, a reduction of 38.0%[31] - Total liabilities decreased significantly to $21,840 in 2024 from $36,109 in 2023, a reduction of 39.4%[29] - The company’s accumulated deficit improved to $(66,630) in 2024 from $(74,481) in 2023, showing a reduction of 10.4%[29] - The conversion of 3.5 million Series A Preferred Stock into common stock will reduce annual dividend burden by $7.7 million[5] - The company reported a preferred stock dividend of $12,310 for the year ended December 31, 2024, down from $15,674 in 2023[31] - The company incurred goodwill impairment charges of $42,000,000 in Q4 2023, which did not recur in Q4 2024[39] Future Projections - The company expects 2025 revenue to be between $111 million and $114 million, based on growth from existing clients and new acquisitions[15] - Adjusted EBITDA for 2025 is projected to be between $26 million and $28 million, reflecting cost reduction efforts[16] Shareholder Information - The total number of end-of-period shares increased to 16,256,236 in Q4 2024 from 15,880,092 in Q4 2023[41] Financial Metrics - Free cash flow is considered an important financial measure for evaluating the Company's performance[61] - Free cash flow does not account for payments required for debt service and other contractual obligations[61] - The Company views free cash flow as supplemental information to its condensed consolidated statements of cash flows[61]

Core Viewpoint - CareCloud, Inc. has achieved a significant turnaround in its financial performance for the year ended December 31, 2024, returning to GAAP profitability, generating record cash flow, resuming dividends, and strengthening its balance sheet [1][4][9] Financial Performance - Full year 2024 revenue was $110.8 million, down from $117.1 million in 2023 [4][6] - GAAP net income for 2024 was $7.9 million, a recovery from a net loss of $48.7 million in 2023 [4][6] - Adjusted net income for 2024 was $10.5 million, or $0.65 per share [4][8] - Adjusted EBITDA for 2024 was $24.1 million, an increase of 56% from $15.4 million in 2023 [6][9] Fourth Quarter Performance - Fourth quarter 2024 revenue was $28.2 million, slightly down from $28.4 million in Q4 2023 [5][6] - GAAP net income for Q4 2024 was $3.3 million, compared to a net loss of $43.7 million in Q4 2023 [6][7] - Adjusted EBITDA for Q4 2024 was $7.1 million, a 73% increase from $4.1 million in the same period last year [6][7] Operational Improvements - The company has successfully transformed its cost structure, enhancing operational efficiency through AI-driven innovations [2][4] - Free cash flow for 2024 was $13.2 million, a substantial increase of 244% from $3.8 million in 2023 [6][9] Shareholder Actions - In January 2025, CareCloud increased the number of authorized common shares from 35 million to 85 million and declared two months of Preferred Stock dividends [3] - The conversion of 3.5 million shares of Series A Preferred Stock into common stock resulted in the issuance of 26 million additional common shares, reducing the annual dividend burden by $7.7 million [3][6] 2025 Guidance - For the fiscal year ending December 31, 2025, CareCloud expects revenue between $111 million and $114 million [12][13] - Adjusted EBITDA is anticipated to be between $26 million and $28 million, with net income per share projected at $0.10 to $0.13 [12][13]

SOMERSET, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- CareCloud, Inc. (the “Company”) (Nasdaq: CCLD, CCLDO, CCLDP), a leader in healthcare information technology and generative AI solutions for medical practices and health systems nationwide, announced today that it will formally notify The Nasdaq Stock Market LLC of its intent to voluntarily delist its 8.75% Series A Cumulative Redeemable Perpetual Preferred Stock (Nasdaq: CCLDP) (“Series A Preferred Stock”) from the Nasdaq Global Market. The Company expects ...

Core Viewpoint - CareCloud, Inc. has announced the mandatory conversion of its 8.75% Series A Cumulative Redeemable Perpetual Preferred Stock into Common Stock, which is expected to eliminate approximately $7 million in annual dividend obligations and improve the company's capital structure [1][2]. Group 1: Conversion Details - The conversion will be effective at 4:01 p.m. Eastern Time on March 6, 2025, with each share of Preferred Stock converting into 7.3358 shares of Common Stock, including all accumulated and unpaid dividends [2][3]. - Shareholders holding at least 100,000 shares of Preferred Stock will retain the right to object to the conversion if their shares are held by the company's transfer agent [3]. Group 2: Financial Implications - The conversion is anticipated to free up capital for reinvestment in growth initiatives, enhancing the company's ability to create shareholder value [2]. - The elimination of dividend obligations is expected to provide greater flexibility in managing the company's financial resources [2]. Group 3: Company Overview - CareCloud specializes in healthcare information technology and generative AI solutions, serving over 40,000 providers to improve patient care while reducing administrative burdens and operating costs [5].

Core Viewpoint - CareCloud, Inc. is resuming its acquisition strategy to enhance its position in the healthcare technology and revenue cycle management sectors, starting with the acquisition of Mesa, LLC, which was finalized on February 28, 2025 [2][3]. Group 1: Acquisition Strategy - The acquisition of Mesa, LLC marks CareCloud's first step in a renewed aggressive expansion strategy, aiming to reinforce its leadership in the healthcare billing industry [2][3]. - CareCloud has a history of successful acquisitions, having completed over 20 deals between 2012 and 2022, achieving a compound annual growth rate (CAGR) of over 30% during that period [3]. - The company is shifting back into high gear for acquisitions after a pause since Q2 2021, with MesaBilling being the starting point for this new phase [3]. Group 2: Market Context - The renewed focus on acquisitions aligns with a growing demand from medical practices for streamlined, technology-enabled financial management solutions [4]. - CareCloud plans to leverage its proprietary technology, including AI-powered revenue cycle management and automation tools, to expand its platform and serve a broader network of healthcare providers [4]. Group 3: Company Overview - CareCloud provides a suite of AI and technology-enabled solutions aimed at improving financial and operational performance, streamlining clinical workflows, and enhancing patient experiences [5]. - The company serves over 40,000 providers, helping them reduce administrative burdens and operating costs while improving patient care [5].

Core Viewpoint - CareCloud, Inc. is set to release its financial results for Q4 and the full year ended December 31, 2024, on March 13, 2025, before market opening, followed by a conference call for investors [1] Financial Results Announcement - The financial results will be disclosed before the market opens on March 13, 2025 [1] - A conference call for investors will take place at 8:30 a.m. Eastern Time on the same day [1] Accessing the Conference Call - Investors can access the live webcast of the conference call and related presentation slides at ir.carecloud.com/events [2] - An audio-only option is available by dialing 201-389-0920 and referencing "CareCloud Fourth Quarter 2024 Results Conference Call" [2] Replay Information - A replay of the conference call and related presentation slides will be available approximately three hours after the call concludes at the same link [3] - An audio-only replay can be accessed by dialing 412-317-6671 with access code 13751992 [3] Company Overview - CareCloud is a leader in healthcare technology and generative AI solutions, helping clients enhance financial and operational performance while improving patient care [4] - The company serves over 40,000 providers, offering solutions such as revenue cycle management, practice management, electronic health records, business intelligence, patient experience management, and digital health [4]